Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemophilia a Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

NCT00851721
View directory record Official record
Conditions
Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
4 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Gene Transfer Study for Hemophilia A

NCT03003533
View directory record Official record
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Sacramento, California • Gainesville, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jun 27, 2026, 1:05 PM EDT
Recruiting Phase 4 Interventional

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

NCT04647227
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 27, 2026, 1:05 PM EDT
Terminated Phase 4 Interventional Results available

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726
View directory record Official record
Conditions
Hemophilia A
Interventions
Moroctocog alfa(AF-CC), Blood draw for laboratory testing
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Jun 27, 2026, 1:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

ASC618 Gene Therapy in Hemophilia A Patients

NCT04676048
View directory record Official record
Conditions
Hemophilia A
Interventions
ASC618
Biological
Lead sponsor
ASC Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

BAX 855 Pediatric Study

NCT02210091
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 11 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jun 27, 2026, 1:05 PM EDT
Terminated Phase 4 Interventional

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673
View directory record Official record
Conditions
Hemophilia A
Interventions
Kogenate (BAY 14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Detroit, Michigan • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Not applicable Interventional

Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia

NCT01090206
View directory record Official record
Conditions
Hemophilia A, Hemophilia B, Vitamin D Deficiency
Interventions
Vitamin D and calcium
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 21 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Jun 27, 2026, 1:05 PM EDT
Completed No phase listed Observational

ATHN 7: Hemophilia Natural History Study

NCT03619863
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

NCT01392547
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
vatreptacog alfa (activated), eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

NCT02548143
View directory record Official record
Conditions
Hemophilia
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

NCT01341912
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Human-cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Jun 27, 2026, 1:05 PM EDT
Completed No phase listed Observational

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

NCT02830477
View directory record Official record
Conditions
Hemophilia A, Congenital
Interventions
Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Biological
Lead sponsor
Bayer
Industry
Eligibility
Male only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Mobile, Alabama • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jun 27, 2026, 1:05 PM EDT
Completed No phase listed Observational

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

NCT00936312
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Jun 27, 2026, 1:05 PM EDT
Completed No phase listed Observational

Handheld Ultrasound (HHUS) for Home Use in Hemophilia

NCT04131920
View directory record Official record
Conditions
Joint Bleed, Hemophilia A
Interventions
handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Device
Lead sponsor
Washington Institute for Coagulation
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 27, 2026, 1:05 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT06703606
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
MARSTACIMAB
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

NCT02137850
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 27, 2026, 1:05 PM EDT
Withdrawn Phase 3 Interventional

Emicizumab PUPs and Nuwiq ITI Study

NCT04030052
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 27, 2026, 1:05 PM EDT
Recruiting Phase 3 Interventional

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Testing of hepatic AAV Vector integration
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
14
States / cities
Rancho Cordova, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 27, 2026, 1:05 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

NCT04644575
View directory record Official record
Conditions
Hemophilia A
Interventions
efanesoctocog alfa (BIVV001)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Not listed
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 27, 2026, 1:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
activated prothrombin complex concentrate (FEIBA)
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
24 Months and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 27, 2026, 1:05 PM EDT